Bifogade filer
CombiGene Q2 2023 EN
Kurs
-0,93%
Prenumeration
Kalender
| Est. tid* | ||
| 2026-02-13 | 08:50 | Bokslutskommuniké 2025 |
| 2025-08-22 | 08:50 | Kvartalsrapport 2025-Q2 |
| 2025-06-18 | - | X-dag ordinarie utdelning LARK 0.00 SEK |
| 2025-06-12 | - | Årsstämma |
| 2025-02-20 | - | Extra Bolagsstämma 2024 |
| 2025-02-14 | - | Bokslutskommuniké 2024 |
| 2024-11-08 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-23 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-24 | - | X-dag ordinarie utdelning LARK 0.00 SEK |
| 2024-05-23 | - | Årsstämma |
| 2024-05-17 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-16 | - | Bokslutskommuniké 2023 |
| 2023-11-10 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-25 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-26 | - | X-dag ordinarie utdelning LARK 0.00 SEK |
| 2023-05-25 | - | Årsstämma |
| 2023-05-12 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-17 | - | Bokslutskommuniké 2022 |
| 2022-11-11 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-25 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-20 | - | X-dag ordinarie utdelning LARK 0.00 SEK |
| 2022-05-19 | - | Årsstämma |
| 2022-05-12 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-17 | - | Bokslutskommuniké 2021 |
| 2021-11-12 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-20 | - | Kvartalsrapport 2021-Q2 |
| 2021-06-07 | - | Split LARK 20:1 |
| 2021-05-26 | - | X-dag ordinarie utdelning LARK 0.00 SEK |
| 2021-05-25 | - | Årsstämma |
| 2021-05-12 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-17 | - | Bokslutskommuniké 2020 |
| 2020-11-13 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-21 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-30 | - | X-dag ordinarie utdelning LARK 0.00 SEK |
| 2020-06-29 | - | Årsstämma |
| 2020-05-14 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-13 | - | Bokslutskommuniké 2019 |
| 2019-11-14 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-21 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-17 | - | Kvartalsrapport 2019-Q1 |
| 2019-05-16 | - | Årsstämma |
| 2019-05-15 | - | X-dag ordinarie utdelning LARK 0.00 SEK |
| 2019-02-14 | - | Bokslutskommuniké 2018 |
| 2018-08-22 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-04 | - | X-dag ordinarie utdelning LARK 0.00 SEK |
| 2018-05-03 | - | Årsstämma |
| 2018-05-03 | - | Kvartalsrapport 2018-Q1 |
| 2018-01-29 | - | Bokslutskommuniké 2017 |
| 2017-11-01 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-17 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-18 | - | Kvartalsrapport 2017-Q1 |
| 2017-05-10 | - | X-dag ordinarie utdelning LARK 0.00 SEK |
| 2017-05-09 | - | Årsstämma |
| 2017-01-31 | - | Bokslutskommuniké 2016 |
| 2017-01-26 | - | Extra Bolagsstämma 2017 |
| 2016-11-17 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-17 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-19 | - | Kvartalsrapport 2016-Q1 |
| 2016-04-05 | - | X-dag ordinarie utdelning LARK 0.00 SEK |
| 2016-04-04 | - | Årsstämma |
| 2016-02-18 | - | Bokslutskommuniké 2015 |
| 2015-11-19 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-20 | - | Kvartalsrapport 2015-Q2 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
April – June 2023
• Net sales: TSEK 1,788 (4,738).
• Other operating revenues: TSEK 1,413 (9,800).
• Profit from financial items: TSEK -6,286 (4,516).
• Earnings per share: SEK -0.32 (0.23).
January – June 2023
• Net sales: TSEK 3,955 (16,141).
• Other operating revenues: TSEK 543 (12,602).
• Profit from financial items: TSEK -20,903 (1,832).
• Earnings per share: SEK -1.06 (0.09).
• Cash and cash equivalents: TSEK 115,442 (125,953).
Events during the period
• Gene Therapy, one of Nature’s journals, publishes an article about CombiGene’s epilepsy project authored by Esbjörn Melin, scientist at CombiGene.
• High activity level in the pain program COZY in preparation of the final preclinical toxicology program in the peptide project COZY01.
• CombiGene to play an integral part in the development of a national infrastructure for ATMPs. CombiGene’s CEO Jan Nilsson elected Chairman of the Board of CCRM Nordic AB.
• CombiGene forms prominent Scientific Advisory Board within the pain program COZY.
• Jan Nilsson leaves his position as CEO of CombiGene – COO Peter Ekolind takes over as new CEO on September 1, 2023.
Events after the end of the period
• There have been no significant events after the end of the period.
Contacts
CombiGene AB (publ)
Jan Nilsson, CEO
Phone: +46 (0)704 66 31 63
jan.nilsson@combigene.com
www.combigene.com
CombiGene AB (publ) Agavägen 52A, SE-181 55 Lidingö, Sweden
+46-8-357355 info@combigene.com
About CombiGene
CombiGene’s vision is to offer patients affected by severe life‐changing diseases opportunities for a better life through innovative gene therapies. CombiGene’s business concept is to develop effective gene therapies for serious diseases that today lack adequate treatment methods. Research assets are taken in from a network of external researchers and developed further up to preclinical/clinical concept verification. Drug candidates for common diseases will be co‐developed and commercialized through strategic partnerships, while CombiGene may drive the development and commercialization in‐house for medicines aimed at limited patient populations.
The company has an exclusive collaboration and license agreement with Spark Therapeutics for the CG01 project and a collaboration agreement with the Danish company Zyneyro within the pain program COZY.
The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, info@fnca.se.
CombiGene’s lead project CG01 has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 823282.
CombiGene´s project CGT2 is supported by the Eurostars Programme. Project ID: 114714